Order Entry
United States
ContactUsLinkComponent
Human Recombinant CA125 (prokaryotic)(from E. coli)
Human Recombinant CA125 (prokaryotic)(from E. coli)
  MSPP-RPA154HU1
 :  
undefined
Human Recombinant CA125 (prokaryotic)(from E. coli)
  MSPP-RPA154HU1
 :  RPA154HU01
 :  

 

  • Pack type:
    Vial
  • Conjugation:
    Unconjugated
  • Protein Function:
    Cytokine
  • Protein/Peptide Type:
    Recombinant
  • Source:
    E. coli
  • Species:
    Human
  • Size:
    50 µg
  • Tag sequence:
    MGHHHHHHSGSEF
  • Storage Conditions:
    –20 °C
  • Endotoxin Content:
    <1.0 EU per 1 μg (determined by the LAL method)
  • Gene ID:
    94025
  • Reconstitution Instructions:
    Reconstitute in 10 mM PBS (pH 7.4) to a concentration of 0.1 - 1.0 mg/ml. Do not vortex.
  • Endotoxin-free:
    N
  • Carrier-Free:
    Y
  • Protease-free:
    N
  • Animal-Free:
    Y
  • Protein Synonyms:
    Carbohydrate Antigen 125
  • UniProtKB:
    Q8WXI7
  • Protein/Peptide Name:
    CA125
  • Purity:
    95 - 100%
  • Molecular Weight:
    26 kDa
  • Sequence:
    Arg13977~Ser14117
  • Endotoxin Level:
    Low
  • Concentration:
    0.2 mg/ml
  • Formulation:
    Lyophilized from PBS, pH 7.4 containing 0.01% SKL, 5% trehalose
  • Nuclease-free:
    N
  • Shipping Temperature:
    4 °C
  • Tested Applications:
    Positive control, Immunogen, SDS-PAGE, Western blot.
  • Cat. No.:
    MSPP-RPA154HU1

 

 

This is a CA125 recombinant protein (prokaryotic), Human is sequencing from Arg13977~Ser14117 with 95 to 100% purity. LyopH ilized from PBS, pH 7.4, containing 0.01% SKL, 5% Trehalose with 0.2 mg/ml.

  • High quality, purity, reproducibility and effectiveness
  • Offers customized buffers and tag options
  • 100% quality and service satisfaction guarantee

CA-125 has found application as a tumor marker or biomarker that may be elevated in the blood of some patients with specific types of cancers. CA-125 is clinically approved for following the response to treatment and predicting prognosis after treatment. It is especially useful for detecting the recurrence of ovarian cancer. Its potential role for the early detection of ovarian cancer is controversial and has not yet been adopted for widespread screening efforts in asymptomatic women. The key problems in using the CA-125 test as a screening tool are its lack of sensitivity and its inability to detect early stage cancers. An operation would be necessary to confirm that a woman with elevated CA-125 has ovarian cancer, with the associated risk of death from major surgery.

 : ISO 9001 and ISO 13485 certified, three level QC system.
 : For research use only. Not for use In clinical diagnostic procedures. Please proper stored each component based on the instruction.